Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome

Park, Sohyeon; Kim, In-Cheol; Kim, Hyungseop; Lee, Cheol Hyun; Hur, Seung‐Ho

doi:10.1007/s00380-021-01905-z

Cited by 8 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eventually, cardiac function is impaired and a range of cardiac diseases can occur, including valvular disease, atrial fibrillation, and coronary heart disease. 12,14,19,[22][23][24][25][26] The present study found that preoperative sST2 levels were negatively correlated with early 27 reported that elevated sST2 levels were independently associated with excess mortality and heart failure after myocardial infarction. Interestingly, data from the Valsartan Heart Failure Trial indicated that an increase in sST2 levels was associated with worse outcomes, but a decrease in sST2 levels did not translate into a better prognosis.…”

Section: Discussionsupporting

confidence: 52%

Preoperative sST2 levels relate to myocardial remodeling and cardiac function improvement after cardiac valve surgery

Zhu,

Pei,

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

AimsWe aim to investigate the correlation between preoperative soluble suppression of tumourigenicity 2 (sST2) and postoperative myocardial remodelling and cardiac function in patients with valvular heart disease.Methods and resultsThis retrospective study included patients who underwent heart valve surgery at the General Hospital of Northern Theatre Command from July 2019 to June 2020. Preoperative, early postoperative, and 1‐month postoperative cardiac ultrasound data were collected. Multivariable linear regression was used to analyse the factors associated with preoperative sST2 and postoperative cardiac function parameters. A receiver operator characteristic curve analysis was used to analyse the predictive value of sST2 for left ventricular ejection fraction (LVEF) reduction at 1 month after surgery. This study included 156 patients. Left ventricular end‐systolic volume (b = 0.125, P = 0.004), atrial fibrillation (b = 7.933, P = 0.003), and coronary artery disease (b = 5.826, P = 0.043) were correlated with the preoperative sST2 levels. Preoperative sST2 was independently associated with early postoperative left ventricular end‐systolic volume (b = −0.136, P = 0.035), left ventricular end‐diastolic volume (b = −0.225, P = 0.036), and LVEF (b = 0.056, P = 0.008). At 1 month after surgery, LVEF (r = −0.234, P = 0.023) and reduction in LVEF (r = −0.316, P = 0.002) were negatively correlated with preoperative sST2. The area under the receiver operator characteristic curve of preoperative sST2 in predicting LVEF reduction at 1 month was 0.646, with a sensitivity of 0.357 and a specificity of 0.918.ConclusionsPreoperative sST2 levels are related to early postoperative myocardial remodelling and have a predictive value for the improvement of cardiac function 1 month after surgery.

show abstract

Section: Discussionsupporting

confidence: 52%

Preoperative sST2 levels relate to myocardial remodeling and cardiac function improvement after cardiac valve surgery

Zhu,

Pei,

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

show abstract

“…As early as 2013, sST2 was recommended by the American College of Cardiology and the American Heart Association as a predictor of hospitalization and death in patients with acute and chronic heart failure [21]. Other larger, clinical studies have since been completed, which also demonstrated elevated sST2 levels in patients with congenital [22] and ischemic [23] heart disease as well as with acute coronary syndrome [24,25]. Additionally, in valvular cardiomyopathies, especially in severe AS, sST2 could be positioned as a relevant biomarker for predictions of mortality and as a relevant criterion for adequate risk stratification [26].…”

Section: Discussionmentioning

confidence: 99%

Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?

Boxhammer

Mirna

Bäz

et al. 2022

Life

View full text Add to dashboard Cite

Background: Severe aortic valve stenosis (AS) is associated with pulmonary hypertension (PH) and has been shown to limit patient survival. Soluble suppression of tumorigenicity-2 (sST2) is a cardiovascular biomarker that has proven to be an important prognostic marker for survival in patients undergoing transcatheter aortic valve replacement (TAVR). The aim of this study was to assess the importance of the sST2 biomarker for risk stratification in patients with severe AS in presence or absence of PH. Methods: In 260 patients with severe AS undergoing TAVR procedure, sST2 serum level concentrations were analyzed. Right heart catheter measurements were performed in 152 patients, with no PH detection in 43 patients and with PH detection in 109 patients. Correlation analyses according to Spearman, AUROC analyses and Kaplan–Meier curves were calculated. Results: Patients with severe AS and PH showed significantly higher serum sST2 concentrations (p = 0.006). The sST2 cut-off value for non-PH patients regarding 1-year survival yielded 5521.15 pg/mL, whereas the cut-off value of PH patients was at a considerably higher level of 10,268.78 pg/mL. A cut-off value of 6990.12 pg/mL was related with a significant probability of PH presence. Survival curves showed that patients with severe AS and PH not only had higher 1-year mortality, but also that increased levels of sST2 plasma concentration were associated with earlier death. Conclusion: sST2 definitely has the potential to provide information about the presence of PH in patients with severe AS, in a noninvasive way.

show abstract

“…Non-correlation was found in relation to ACS types. A multivariable analysis showed that sST2 variation was the most important determinant of LV remodeling following the revascularization of ACS [ 28 ].…”

Section: The Clinical Settingmentioning

confidence: 99%

Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infection—A Narrative Review on Pathophysiology and Clinical Prospective

Marino

Concistrè

Suppa

et al. 2022

IJMS

View full text Add to dashboard Cite

The importance of cardiovascular biomarkers in clinical practice increased dramatically in the last years, and the interest extends from the diagnosis purpose to prognostic applications and response to specific treatment. Acute heart failure, ischemic heart failure, and COVID-19 infection represent different clinical settings that are challenging in terms of the proper prognostic establishment. The aim of the present review is to establish the useful role of sST2, the soluble form of the interleukin-1 receptor superfamily (ST2), physiologically involved in the signaling of interleukin-33 (IL-33)-ST2 axis, in the clinical setting of acute heart failure (HF), ischemic heart disease, and SARS-CoV-2 acute infection. Molecular mechanisms associated with the IL33/ST2 signaling pathways are discussed in view of the clinical usefulness of biomarkers to early diagnosis, evaluation therapy to response, and prediction of adverse outcomes in cardiovascular diseases.

show abstract

Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome

Cited by 8 publications

References 30 publications

Preoperative sST2 levels relate to myocardial remodeling and cardiac function improvement after cardiac valve surgery

Preoperative sST2 levels relate to myocardial remodeling and cardiac function improvement after cardiac valve surgery

Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?

Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infection—A Narrative Review on Pathophysiology and Clinical Prospective

Contact Info

Product

Resources

About